Isofredil

Amisulpride, the active ingredient in Isofredil, is a benzamide antipsychotic presented as an oral tablet for oral use. It is employed in the management of schizophrenia and certain depressive disorders, acting on dopamine pathways to modulate symptoms in adult patients.

GNH USA supplies Isofredil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution. Customers benefit from reliable lead times and dedicated technical support.

Isofredil (amisulpride) acts on dopaminergic pathways and is indicated for several psychiatric conditions. - Schizophrenia: reduces positive and negative symptoms and improves overall functioning. - Depressive disorders (e.g., dysthymia): alleviates persistent low mood and associated symptoms. - Psychotic symptoms in mood disorders: helps control hallucinations and delusions when they occur alongside depressive or bipolar episodes.

Amisulpride may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Headache: transient cranial discomfort. - Insomnia: difficulty initiating or maintaining sleep. - Anxiety: heightened nervousness or tension. - Weight gain: modest increase in body weight. - Extrapyramidal symptoms: tremor, rigidity, or akathisia.

Serious or Rare Side Effects: - Hyperprolactinemia: elevated prolactin leading to galactorrhea or menstrual disturbances. - QT interval prolongation: potential cardiac arrhythmia risk. - Neuroleptic malignant syndrome: rare but life‑threatening reaction with fever and muscle rigidity. - Severe extrapyramidal reactions: persistent dystonia or parkinsonism. - Agranulocytosis: marked reduction in white blood cells. - Severe hypotension: sudden drop in blood pressure, especially on standing.

Before initiating therapy with Isofredil, clinicians should consider several safety measures. - Monitor prolactin levels: assess for signs of hyperprolactinemia during treatment. - Evaluate cardiac function: obtain baseline ECG and monitor QT interval, especially in patients with cardiac risk factors. - Adjust for renal impairment: dose may need modification in reduced kidney function. - Avoid abrupt discontinuation: taper gradually to minimise withdrawal or relapse. - Check for hypersensitivity: discontinue if allergic reactions occur. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Amisulpride can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concurrent QT‑prolonging agents: increase risk of cardiac arrhythmias. - Strong CYP2D6 inhibitors (if co‑administered): may raise plasma concentrations. - Other dopamine antagonists: amplify extrapyramidal side effects.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs: may worsen cognitive side effects. - Diuretics: can affect electrolyte balance and influence QT interval. - CNS depressants (e.g., benzodiazepines): may enhance sedation. - Antihistamines: potential additive anticholinergic burden.